File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1086/432008
- Scopus: eid_2-s2.0-23244456655
- PMID: 16028136
- WOS: WOS:000231019500015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice
Title | Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice |
---|---|
Authors | |
Issue Date | 2005 |
Publisher | Oxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org |
Citation | Journal Of Infectious Diseases, 2005, v. 192 n. 4, p. 665-672 How to Cite? |
Abstract | Background. Control of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic. Methods. BALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN 1203/04) virus. Five- and 8-day regimens were evaluated. Results. Oseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P < .01). The 5-day regimen at 10 mg/kg/day protected 50% of mice; deaths in this treatment group were delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively (P < .05). Overall, the efficacy of the 5- and 8-day regimens differed significantly (death hazard ratio, 2.658; P < .01). The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect. Conclusions. Oseltamivir prophylaxis is efficacious against lethal challenge with VN1203/04 virus in mice. Viral virulence may affect the antiviral treatment schedule. © 2005 by the Infectious Diseases Society of America. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/179783 |
ISSN | 2023 Impact Factor: 5.0 2023 SCImago Journal Rankings: 2.387 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yen, HL | en_US |
dc.contributor.author | Monto, AS | en_US |
dc.contributor.author | Webster, RG | en_US |
dc.contributor.author | Govorkova, EA | en_US |
dc.date.accessioned | 2012-12-19T10:04:34Z | - |
dc.date.available | 2012-12-19T10:04:34Z | - |
dc.date.issued | 2005 | en_US |
dc.identifier.citation | Journal Of Infectious Diseases, 2005, v. 192 n. 4, p. 665-672 | en_US |
dc.identifier.issn | 0022-1899 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/179783 | - |
dc.description.abstract | Background. Control of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic. Methods. BALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN 1203/04) virus. Five- and 8-day regimens were evaluated. Results. Oseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P < .01). The 5-day regimen at 10 mg/kg/day protected 50% of mice; deaths in this treatment group were delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively (P < .05). Overall, the efficacy of the 5- and 8-day regimens differed significantly (death hazard ratio, 2.658; P < .01). The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect. Conclusions. Oseltamivir prophylaxis is efficacious against lethal challenge with VN1203/04 virus in mice. Viral virulence may affect the antiviral treatment schedule. © 2005 by the Infectious Diseases Society of America. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Oxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org | en_US |
dc.relation.ispartof | Journal of Infectious Diseases | en_US |
dc.subject.mesh | Acetamides - Administration & Dosage | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antiviral Agents - Administration & Dosage | en_US |
dc.subject.mesh | Brain - Virology | en_US |
dc.subject.mesh | Cell Line | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Drug Administration Schedule | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Guanidines | en_US |
dc.subject.mesh | Influenza A Virus - Drug Effects - Pathogenicity | en_US |
dc.subject.mesh | Inhibitory Concentration 50 | en_US |
dc.subject.mesh | Lung - Virology | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mice, Inbred Balb C | en_US |
dc.subject.mesh | Orthomyxoviridae Infections - Drug Therapy | en_US |
dc.subject.mesh | Oseltamivir | en_US |
dc.subject.mesh | Pyrans | en_US |
dc.subject.mesh | Sialic Acids - Pharmacology | en_US |
dc.subject.mesh | Virulence | en_US |
dc.subject.mesh | Virus Replication - Drug Effects | en_US |
dc.subject.mesh | Zanamivir | en_US |
dc.title | Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yen, HL: hyen@hku.hk | en_US |
dc.identifier.authority | Yen, HL=rp00304 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1086/432008 | en_US |
dc.identifier.pmid | 16028136 | - |
dc.identifier.scopus | eid_2-s2.0-23244456655 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-23244456655&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 192 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.spage | 665 | en_US |
dc.identifier.epage | 672 | en_US |
dc.identifier.isi | WOS:000231019500015 | - |
dc.publisher.place | United States | en_US |
dc.identifier.f1000 | 1027117 | - |
dc.identifier.scopusauthorid | Yen, HL=7102476668 | en_US |
dc.identifier.scopusauthorid | Monto, AS=7004552306 | en_US |
dc.identifier.scopusauthorid | Webster, RG=36048363100 | en_US |
dc.identifier.scopusauthorid | Govorkova, EA=7003837718 | en_US |
dc.identifier.issnl | 0022-1899 | - |